Winkelmann, Alexander
Metze, Christoph
Zettl, Uwe K.
Loebermann, Micha
Funding for this research was provided by:
Universitätsmedizin Rostock
Article History
Received: 7 May 2023
Accepted: 24 August 2023
First Online: 2 September 2023
Competing interests
: A. Winkelmann reports personal compensation from Bayer Healthcare, Celgene, Merck, Novartis, Sanofi Genzyme, and Teva. C. Metze reports no disclosures. U. K. Zettl received speaking fees, travel support and financial support for research activities from Alexion, Almirall, Bayer, Biogen, Merck Serono, Novartis, Octapharm, Roche, Sanofi Genzyme, Teva and as well as EU, BMBF, BMWi, and DFG. None resulted in a conflict of interest. M. Loebermann reports personal compensation from Gilead, Janssen, Pfizer and Sanofi and research support from Cempra, Correvio, Pfizer, Sanofi, Schering, Seqirus, Themis Bioscience, Valneva and Vectura.